Covered recipient · General Payments record
ROBERTO CARICCHIO
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
General Payments · PY2019–2024
$49,703.42
- Reported across 44 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $21,710.00 | 2 |
| Food and Beverage | $531.70 | 14 |
| Travel and Lodging | $150.00 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $14,192.48 | 10 |
| Merck Sharp & Dohme Corporation | $8,063.48 | 5 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $110.88 | 1 |
| Amgen Inc. | $24.86 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $9.06 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103416223 | CMS |
| ABBVIE INC. | $7.62 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103416225 | CMS |
| ABBVIE INC. | $22.11 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103416227 | CMS |
| ABBVIE INC. | $106.92 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103416229 | CMS |
| ABBVIE INC. | $16.42 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103416231 | CMS |
| ABBVIE INC. | $17.39 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103416233 | CMS |
| ABBVIE INC. | $8.23 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103416235 | CMS |
| ABBVIE INC. | $22.11 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103416237 | CMS |
| ABBVIE INC. | $7.62 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103416239 | CMS |
| ABBVIE INC. | $13,975.00 | 06/21/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1103132579 | CMS |
| Amgen Inc. | $24.86 | 11/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115481400 | CMS |
| Merck Sharp & Dohme LLC | $54.55 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141651665 | CMS |
| Merck Sharp & Dohme LLC | $59.27 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141651667 | CMS |
| Merck Sharp & Dohme LLC | $64.66 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141651669 | CMS |
| Merck Sharp & Dohme LLC | $7,735.00 | 11/11/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141639797 | CMS |
| Merck Sharp & Dohme LLC | $150.00 | 11/11/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1141639799 | CMS |
| Novartis Pharmaceuticals Corporation | $110.88 | 11/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086780741 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.